815
Views
0
CrossRef citations to date
0
Altmetric
Review

New-generation androgen receptor signaling inhibitors (ARSIs) in metastatic hormone-sensitive prostate cancer (mHSPC): pharmacokinetics, drug-drug interactions (DDIs), and clinical impact

ORCID Icon, ORCID Icon, , &
Pages 491-502 | Received 10 Mar 2024, Accepted 07 May 2024, Published online: 22 May 2024

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.